Filtered By:
Drug: Carbidopa/Levodopa
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk
[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared to those taking carbidopa/levodopa (sold as the combination product, Sinemet).
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2016 Category: Drugs & Pharmacology Source Type: news
